Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

13.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
13.0K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Negative Regulator Molecules01:23

Negative Regulator Molecules

35.3K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cd99l2 regulates excitatory synapse development and restrains immediate-early gene activation.

Cell reports·2026
Same author

Engineered flower-like core-double-shell upconversion nanoarchitectures for ultrasensitive activatable FRET imaging of cathepsin B in vitro and in vivo.

Talanta·2026
Same author

Enhanced multicancer screening assay through whole-genome methylation sequencing-based multimodal cell-free DNA analysis.

Experimental & molecular medicine·2026
Same author

Correction: Peptide‑based therapeutics targeting the SLC39A14‑PIWIL2 fusion in hepatocellular carcinoma.

Genomics & informatics·2026
Same author

QStrain: an interactive platform for viral genome analysis and nucleic acid therapeutic design.

BMC bioinformatics·2026
Same author

NetCrafter: ontology-derived gene network modeling and functional interpretation.

Briefings in bioinformatics·2026
Same journal

Corrigendum.

Anticancer research·2026
Same journal

Geographic Variation in Stage at Diagnosis of Skin Cancer in the United States: A National Cancer Database Analysis.

Anticancer research·2026
Same journal

Anti-tumor Effects of Loureirin A Treatment in Colorectal Cancer Cells <i>via</i> Inhibition of AKT Phosphorylation.

Anticancer research·2026
Same journal

Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab <i>vs</i>. Sunitinib) for Advanced Renal Cell Carcinoma.

Anticancer research·2026
Same journal

Pulsed Electromagnetic Field Increases Doxorubicin-induced Mitotic Slippage in MDA-MB-231 Breast Cancer Cells.

Anticancer research·2026
Same journal

Geographic Disparities in Socioeconomic Factors and Advanced-stage Presentation in Rectosigmoid Cancer: A National Cancer Database Analysis.

Anticancer research·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2025

In vitro Organoid Culture of Primary Mouse Colon Tumors
07:33

In vitro Organoid Culture of Primary Mouse Colon Tumors

Published on: May 17, 2013

35.1K

RRM2 Is a CTNNB1 Transport Regulator Promoting Colon Cancer Progression.

Sung Ung Moon1, Jong Hyeon Lee1, Masaud Shah1

  • 1Department of Physiology, Ajou University School of Medicine, Suwon, Republic of Korea.

Anticancer Research
|May 31, 2024
PubMed
Summary
This summary is machine-generated.

Ribonucleoside-diphosphate reductase subunit M2 (RRM2) knockdown inhibits tumor growth by reducing beta-catenin (CTNNB1) nuclear translocation. This finding highlights RRM2 as a potential therapeutic target for cancer treatment.

Keywords:
CTNNB1MultiplexRRM2WntsiRNA library screeningtranslocation

More Related Videos

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.5K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.5K

Related Experiment Videos

Last Updated: Jun 25, 2025

In vitro Organoid Culture of Primary Mouse Colon Tumors
07:33

In vitro Organoid Culture of Primary Mouse Colon Tumors

Published on: May 17, 2013

35.1K
Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.5K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.5K

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Oncogenesis

Background:

  • CTNNB1 (beta-catenin) stabilization in the cytoplasm promotes tumor growth.
  • Wnt signaling pathways are critical in regulating CTNNB1 function.
  • Understanding CTNNB1 modulation is key to developing cancer therapies.

Purpose of the Study:

  • Investigate the role of ribonucleoside-diphosphate reductase subunit M2 (RRM2) in modulating CTNNB1 function.
  • Identify novel targets for regulating CTNNB1 in tumor progression.
  • Explore RRM2 as a potential therapeutic target in cancer.

Main Methods:

  • Multiplex siRNA library screening to identify genes affecting CTNNB1 nuclear translocation.
  • RRM2 knockdown experiments in colon cancer cell lines.
  • Assays for cell viability, sphere formation, invasion, immunoprecipitation, immunoblotting, immunocytochemistry, and RT-qPCR to analyze RRM2-CTNNB1 interaction and oncogenic impact.

Main Results:

  • Identified 26 candidate genes involved in CTNNB1 nuclear translocation via siRNA screening.
  • Validated that RRM2 knockdown significantly reduces CTNNB1 nuclear translocation.
  • Observed a decrease in colon cancer cell count and suppressed tumor cell growth upon RRM2 inhibition.

Conclusions:

  • High-throughput siRNA screening is effective for identifying cancer-related gene functions.
  • The interaction between RRM2 and CTNNB1 presents a promising drug target.
  • Targeting the RRM2-CTNNB1 pathway offers a strategy for cancer treatment.